Current Treatments and New, Tentative Therapies for Parkinson’s Disease

  1. Pardo-Moreno, Teresa 5
  2. García-Morales, Victoria 6
  3. Suleiman-Martos, Sami 1
  4. Rivas-Domínguez, Antonio 3
  5. Mohamed-Mohamed, Himan 4
  6. Ramos-Rodríguez, Juan José 4
  7. Melguizo-Rodríguez, Lucía 27
  8. González-Acedo, Anabel 2
  1. 1 Servicio Andaluz de Salud, Avd. del Sur 11, 18014 Granada, Spain
  2. 2 Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
  3. 3 Department of Celular Biology, University of Seville, 41009 Seville, Spain
  4. 4 Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
  5. 5 Primary Health Care, Instituto Nacional de Gestión Sanitaria (INGESA), 51003 Ceuta, Spain
  6. 6 Physiology Area, Department of Biomedicine, Biotechnology and Public Health, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
  7. 7 Instituto de Investigación Biosanitaria, Ibs Granada, Av. de Madrid, 15, 18012 Granada, Spain
Revista:
Pharmaceutics

ISSN: 1999-4923

Año de publicación: 2023

Volumen: 15

Número: 3

Páginas: 770

Tipo: Artículo

DOI: 10.3390/PHARMACEUTICS15030770 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Pharmaceutics

Información de financiación

Financiadores

  • Junta de Andalucía
    • P18-RT-3324
    • P20-01293
    • P20-01061
  • Ministry of Science and Innovation
    • PID2019-110960GB-I00

Referencias bibliográficas

  • Kalia, (2015), Lancet, 386, pp. 896, 10.1016/S0140-6736(14)61393-3
  • Lew, (2007), Pharmacotherapy, 27, pp. 155S, 10.1592/phco.27.12part2.155S
  • Driver, (2009), Neurology, 72, pp. 432, 10.1212/01.wnl.0000341769.50075.bb
  • Lai, (2003), Mol. Neurobiol., 27, pp. 137, 10.1385/MN:27:2:137
  • Tysnes, (2017), J. Neural Transm., 124, pp. 901, 10.1007/s00702-017-1686-y
  • Ou, (2021), Front. Public Health, 9, pp. 776847, 10.3389/fpubh.2021.776847
  • Hobson, (2015), Int. J. Geriatr. Psychiatry, 30, pp. 1048, 10.1002/gps.4261
  • Palmqvist, (2015), Lancet, 385, pp. S27, 10.1016/S0140-6736(15)60822-4
  • Chen, (2021), J. Park. Dis., 11, pp. 919
  • Cerri, (2019), J. Park. Dis., 9, pp. 501
  • Meles, (2021), Mol. Med., 27, pp. 111, 10.1186/s10020-021-00327-x
  • Chan, (2022), Sci. Rep., 12, pp. 4021, 10.1038/s41598-022-07957-z
  • Tolosa, (2021), Lancet Neurol., 20, pp. 385, 10.1016/S1474-4422(21)00030-2
  • Camahuali, (2020), Park. Dis., 2020, pp. e9106026
  • Zhang, (2022), JAMA Netw. Open, 5, pp. e2227738, 10.1001/jamanetworkopen.2022.27738
  • Balestrino, (2020), Eur. J. Neurol., 27, pp. 27, 10.1111/ene.14108
  • Mehndiratta, (2011), J. Assoc. Physicians India, 59, pp. 302
  • Inzelberg, (2002), Am. J. Med. Genet., 111, pp. 459, 10.1002/ajmg.10586
  • Zareparsi, (2002), Am. J. Med. Genet., 111, pp. 461, 10.1002/ajmg.10581
  • Tanner, (2003), Am. J. Epidemiol., 157, pp. 1015, 10.1093/aje/kwg068
  • Schaeffer, (2020), Prog. Brain Res., 252, pp. 331, 10.1016/bs.pbr.2020.01.003
  • Wakabayashi, (2013), Mol. Neurobiol., 47, pp. 495, 10.1007/s12035-012-8280-y
  • Alexander, (1986), Annu. Rev. Neurosci., 9, pp. 357, 10.1146/annurev.ne.09.030186.002041
  • Groenewegen, (2003), Neural Plast., 10, pp. 107, 10.1155/NP.2003.107
  • Jankovic, (2020), J. Neurol. Neurosurg. Psychiatry, 91, pp. 795, 10.1136/jnnp-2019-322338
  • Kordower, (2008), Nat. Med., 14, pp. 504, 10.1038/nm1747
  • Chu, (2010), Ann. N. Y. Acad. Sci., 1184, pp. 55, 10.1111/j.1749-6632.2009.05229.x
  • Obeso, (2010), Nat. Med., 16, pp. 653, 10.1038/nm.2165
  • Chaudhuri, (2010), Prog. Brain Res., 184, pp. 325, 10.1016/S0079-6123(10)84017-8
  • Davie, (2008), Br. Med. Bull., 86, pp. 109, 10.1093/bmb/ldn013
  • Lyons, (2011), Am. J. Manag. Care, 17, pp. S308
  • Bidesi, (2021), J. Neurochem., 159, pp. 660, 10.1111/jnc.15516
  • Spillantini, (1997), Nature, 388, pp. 839, 10.1038/42166
  • Brundin, (2017), J. Neurosci., 37, pp. 9808, 10.1523/JNEUROSCI.1788-16.2017
  • Uchihara, (2016), Acta Neuropathol., 131, pp. 49, 10.1007/s00401-015-1485-1
  • Borghammer, (2021), J. Park. Dis., 11, pp. 455
  • Borghammer, (2019), J. Park. Dis., 9, pp. S281
  • Horsager, (2020), Brain, 143, pp. 3077, 10.1093/brain/awaa238
  • Borghammer, (2021), Neurobiol. Dis., 161, pp. 105557, 10.1016/j.nbd.2021.105557
  • Cardoso, (2019), Mucosal Immunol., 12, pp. 10, 10.1038/s41385-018-0063-y
  • Raybould, (2015), Physiol. Behav., 139, pp. 188, 10.1016/j.physbeh.2014.10.032
  • Derkinderen, (2019), J. Park. Dis., 9, pp. S323
  • Obrenovich, M.E.M. (2018). Leaky Gut, Leaky Brain?. Microorganisms, 6.
  • Pajares, M., Rojo, A.I., Manda, G., Boscá, L., and Cuadrado, A. (2020). Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications. Cells, 9.
  • Rathnayake, D., Chang, T., and Udagama, P. (2019). Selected Serum Cytokines and Nitric Oxide as Potential Multi-Marker Biosignature Panels for Parkinson Disease of Varying Durations: A Case-Control Study. BMC Neurol., 19.
  • Rietdijk, (2017), Front. Neurol., 8, pp. 37, 10.3389/fneur.2017.00037
  • Braak, (2003), J. Neural Transm., 110, pp. 517, 10.1007/s00702-002-0808-2
  • Meiser, (2013), Cell Commun. Signal., 11, pp. 34, 10.1186/1478-811X-11-34
  • Lee, (2011), Neurosci. Res., 70, pp. 339, 10.1016/j.neures.2011.05.008
  • Horvath, (2015), Sci. Rep., 5, pp. 10422, 10.1038/srep10422
  • Chou, (2018), Park. Relat. Disord., 51, pp. 9, 10.1016/j.parkreldis.2018.02.001
  • Comi, (2014), Park. Relat. Disord., 20, pp. 1329, 10.1016/j.parkreldis.2014.10.010
  • Mu, (2013), J. Neuropathol. Exp. Neurol., 72, pp. 614, 10.1097/NEN.0b013e3182965886
  • Cersosimo, (2012), Neurobiol. Dis., 46, pp. 559, 10.1016/j.nbd.2011.10.014
  • Beach, (2010), Acta Neuropathol., 119, pp. 689, 10.1007/s00401-010-0664-3
  • Miki, (2010), Neurosci. Lett., 469, pp. 357, 10.1016/j.neulet.2009.12.027
  • Westerink, (2006), CNS Neurol. Disord. Drug Targets, 5, pp. 57, 10.2174/187152706784111597
  • Latif, (2021), Clin. Chim. Acta Int. J. Clin. Chem., 522, pp. 114, 10.1016/j.cca.2021.08.009
  • Zhang, (2019), ACS Chem. Neurosci., 10, pp. 945, 10.1021/acschemneuro.8b00454
  • Khan, (2019), Int. J. Neurosci., 129, pp. 55, 10.1080/00207454.2018.1486837
  • Kang, (2022), Front. Neurol., 13, pp. 915232, 10.3389/fneur.2022.915232
  • Lang, (2022), N. Engl. J. Med., 387, pp. 408, 10.1056/NEJMoa2203395
  • LeWitt, (2015), Mov. Disord., 30, pp. 64, 10.1002/mds.26082
  • Adamiak, (2010), Clin. Neuropharmacol., 33, pp. 135, 10.1097/WNF.0b013e3181d47849
  • Yuan, (2010), Neurosci. Bull., 26, pp. 66, 10.1007/s12264-010-0302-z
  • Poewe, (2017), Nat. Rev. Dis. Primers, 3, pp. 17013, 10.1038/nrdp.2017.13
  • Antonini, (2008), Neurol. Sci., 29, pp. S371, 10.1007/s10072-008-1049-4
  • Oertel, (2016), J. Neurochem., 139, pp. 325, 10.1111/jnc.13750
  • (2015), Drugs, 75, pp. 157, 10.1007/s40265-014-0343-0
  • Dhanawat, (2020), Cent. Nerv. Syst. Agents Med. Chem., 20, pp. 88, 10.2174/1871524920666200705222842
  • Binde, (2020), Eur. J. Clin. Pharmacol., 76, pp. 1731, 10.1007/s00228-020-02961-6
  • Kulisevsky, (2010), Drug Saf., 33, pp. 147, 10.2165/11319860-000000000-00000
  • Carbone, (2019), CNS Drugs, 33, pp. 905, 10.1007/s40263-019-00661-z
  • Armstrong, (2020), JAMA, 323, pp. 548, 10.1001/jama.2019.22360
  • Nijhuis, (2021), Mov. Disord., 36, pp. 1293, 10.1002/mds.28599
  • Dijk, (2020), J. Park. Dis., 10, pp. S65
  • Atchley, (2020), J. Neurosurg., 1–5, pp. 279, 10.3171/2020.5.JNS20125
  • (2015), Psychiatr. Pol., 49, pp. 791, 10.12740/PP/25162
  • Krauss, (2021), Nat. Rev. Neurol., 17, pp. 75, 10.1038/s41582-020-00426-z
  • Fox, (2018), Mov. Disord., 33, pp. 1248, 10.1002/mds.27372
  • Armstrong, (2020), JAMA, 323, pp. 1420, 10.1001/jama.2020.1224
  • Afentou, (2019), Mov. Disord. Clin. Pract., 6, pp. 282, 10.1002/mdc3.12755
  • Church, F.C. (2021). Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease. Biomolecules, 11.
  • Pontone, (2021), Am. J. Geriatr. Psychiatry, 29, pp. 530, 10.1016/j.jagp.2021.02.037
  • Egan, (2015), J. Park. Dis., 5, pp. 443
  • Fanciulli, (2021), Lancet Neurol., 20, pp. 781, 10.1016/S1474-4422(21)00292-1
  • Palma, (2018), Mov. Disord., 33, pp. 372, 10.1002/mds.27344
  • Chen, (2020), Neurobiol. Dis., 134, pp. 104700, 10.1016/j.nbd.2019.104700
  • Schapira, (2017), Nat. Rev. Neurosci., 18, pp. 435, 10.1038/nrn.2017.62
  • Park, (2009), J. Neurol., 256, pp. 293, 10.1007/s00415-009-5240-1
  • Leung, (2015), Neurology, 85, pp. 1843, 10.1212/WNL.0000000000002145
  • Lawrence, (2018), Park. Dis., 2018, pp. 4318475
  • Orgeta, (2020), Cochrane Database Syst. Rev., 2, pp. CD011961
  • Taximaimaiti, (2021), Curr. Neuropharmacol., 19, pp. 2233, 10.2174/1570159X19666210517115706
  • Stefani, (2020), Neuropsychopharmacology, 45, pp. 121, 10.1038/s41386-019-0448-y
  • Hill, (2014), Nat. Rev. Gastroenterol. Hepatol., 11, pp. 506, 10.1038/nrgastro.2014.66
  • Sanders, (2019), Nat. Rev. Gastroenterol. Hepatol., 16, pp. 605, 10.1038/s41575-019-0173-3
  • Rastall, (2019), Appl. Microbiol. Biotechnol., 103, pp. 6463, 10.1007/s00253-019-09978-7
  • Tan, (2021), Neurology, 96, pp. e772
  • Du, X., Xie, X., and Liu, R. (2020). The Role of α-Synuclein Oligomers in Parkinson’s Disease. Int. J. Mol. Sci., 21.
  • Borzabadi, (2018), Arch. Iran. Med., 21, pp. 289
  • Tamtaji, (2019), Clin. Nutr. Edinb. Scotl., 38, pp. 1031, 10.1016/j.clnu.2018.05.018
  • Koszła, O., Stępnicki, P., Zięba, A., Grudzińska, A., Matosiuk, D., and Kaczor, A.A. (2021). Current Approaches and Tools Used in Drug Development against Parkinson’s Disease. Biomolecules, 11.
  • Elkouzi, (2019), Nat. Rev. Neurol., 15, pp. 204, 10.1038/s41582-019-0155-7
  • Poewe, (2020), Neuropharmacology, 171, pp. 108085, 10.1016/j.neuropharm.2020.108085
  • Parkinson Study Group (2020). STEADY-PD III Investigators Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann. Intern. Med., 172, 591–598.
  • Masaldan, (2019), Free Radic. Biol. Med., 133, pp. 221, 10.1016/j.freeradbiomed.2018.09.033
  • Ward, (2017), Sci. Rep., 7, pp. 1398, 10.1038/s41598-017-01402-2
  • Cheong, (2020), J. Park. Dis., 10, pp. 775
  • Agostini, F., Masato, A., Bubacco, L., and Bisaglia, M. (2021). Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges. Int. J. Mol. Sci., 23.
  • Gelders, (2018), J. Immunol. Res., 2018, pp. 4784268, 10.1155/2018/4784268
  • Caggiu, (2019), Front. Neurol., 10, pp. 122, 10.3389/fneur.2019.00122
  • Lee, J.H., Kim, H.J., Kim, J.U., Yook, T.H., Kim, K.H., Lee, J.Y., and Yang, G. (2021). A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer’s and Parkinson’s Disease. Int. J. Mol. Sci., 22.
  • Gordon, (2018), Sci. Transl. Med., 10, pp. eaah4066, 10.1126/scitranslmed.aah4066
  • Lashgari, (2021), J. Neuroimmunol., 361, pp. 577758, 10.1016/j.jneuroim.2021.577758
  • Yan, (2018), Clin. Immunol., 189, pp. 4, 10.1016/j.clim.2016.09.014
  • Levin, (2019), Lancet Neurol., 18, pp. 724, 10.1016/S1474-4422(19)30141-3
  • Hu, (2021), Neurobiol. Dis., 160, pp. 105527, 10.1016/j.nbd.2021.105527
  • Price, (2018), Sci. Rep., 8, pp. 16165, 10.1038/s41598-018-34490-9
  • Teng, (2021), CNS Neurol. Disord. Drug Targets, 20, pp. 802, 10.2174/1871527320666210526160926
  • Pagano, (2022), N. Engl. J. Med., 387, pp. 421, 10.1056/NEJMoa2202867
  • Poewe, (2021), J. Park. Dis., 11, pp. 1079
  • Nimmo, (2020), Alzheimers Res. Ther., 12, pp. 159, 10.1186/s13195-020-00727-x
  • Menon, (2022), Front. Neurol., 13, pp. 852003, 10.3389/fneur.2022.852003
  • Gronich, (2018), Mov. Disord., 33, pp. 1465, 10.1002/mds.108
  • Mittal, (2017), Science, 357, pp. 891, 10.1126/science.aaf3934
  • Magistrelli, (2020), J. Neuroimmune Pharmacol., 15, pp. 74, 10.1007/s11481-018-09831-0
  • Koros, (2017), Int. Rev. Neurobiol., 132, pp. 197, 10.1016/bs.irn.2017.01.009
  • Chen, C.-L., Wang, S.-Y., Chen, T.-C., and Chuang, C.-S. (2021). Association between Β2-Adrenoreceptor Medications and Risk of Parkinson’s Disease: A Meta-Analysis. Medicina, 57.
  • Pérez-Carrión, M.D., Posadas, I., Solera, J., and Ceña, V. (2022). LRRK2 and Proteostasis in Parkinson’s Disease. Int. J. Mol. Sci., 23.
  • Jennings, (2022), Sci. Transl. Med., 14, pp. eabj2658, 10.1126/scitranslmed.abj2658
  • Senkevich, (2021), Acta Nat., 13, pp. 70, 10.32607/actanaturae.11031
  • Sun, C., and Armstrong, M.J. (2021). Treatment of Parkinson’s Disease with Cognitive Impairment: Current Approaches and Future Directions. Behav. Sci., 11.
  • Huang, (2019), Medicine, 98, pp. e16163, 10.1097/MD.0000000000016163
  • Rodrigues, (2022), Sci. Rep., 12, pp. 4168, 10.1038/s41598-022-08076-5
  • Kuai, (2021), Microb. Cell Factories, 20, pp. 98, 10.1186/s12934-021-01589-0
  • Yu, (2018), Sci. Rep., 8, pp. 567, 10.1038/s41598-017-16790-8
  • Segal, (2021), Clin. Neurol. Neurosurg., 207, pp. 106791, 10.1016/j.clineuro.2021.106791
  • Zhao, (2021), Microbiome, 9, pp. 226, 10.1186/s40168-021-01107-9
  • Sun, (2018), Brain. Behav. Immun., 70, pp. 48, 10.1016/j.bbi.2018.02.005
  • Zhong, (2021), Neurochem. Res., 46, pp. 3050, 10.1007/s11064-021-03411-0
  • Xue, (2020), Medicine, 99, pp. e22035, 10.1097/MD.0000000000022035
  • Tang, (2017), Neurosci. Bull., 33, pp. 568, 10.1007/s12264-017-0123-4
  • Rodrigues, (2014), Drugs Aging, 31, pp. 239, 10.1007/s40266-014-0160-x
  • Bowers, (1997), Exp. Neurol., 144, pp. 58, 10.1006/exnr.1996.6389
  • Lindholm, (2022), Mol. Psychiatry, 27, pp. 1310, 10.1038/s41380-021-01394-6
  • Slevin, (2007), J. Neurosurg., 106, pp. 614, 10.3171/jns.2007.106.4.614
  • Ren, (2013), Exp. Neurol., 248, pp. 148, 10.1016/j.expneurol.2013.06.002
  • Yousefi, (2020), J. Cell. Physiol., 235, pp. 9166, 10.1002/jcp.29800
  • Morizane, (2019), Rinsho Shinkeigaku, 59, pp. 119, 10.5692/clinicalneurol.cn-001235
  • Elsworth, (2020), J. Neural Transm., 127, pp. 785, 10.1007/s00702-020-02167-1
  • Kolagar, (2020), Curr. Stem Cell Res. Ther., 15, pp. 102, 10.2174/1574888X14666190823142911
  • Stoddard-Bennett, T., and Reijo Pera, R. (2019). Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells, 8.
  • Doi, (2020), Nat. Commun., 11, pp. 3369, 10.1038/s41467-020-17165-w
  • Bunt, L., Hoskyns, S., and Swami, S. (2013). The Handbook of Music Therapy, Routledge.
  • Sharma, (2021), Front. Integr. Neurosci., 15, pp. 769142, 10.3389/fnint.2021.769142
  • Matziorinis, (2022), Ann. N. Y. Acad. Sci., 1516, pp. 11, 10.1111/nyas.14864
  • Zhou, (2021), Clin. Rehabil., 35, pp. 937, 10.1177/0269215521990526
  • Marmelat, (2020), Gait Posture, 80, pp. 234, 10.1016/j.gaitpost.2020.05.021
  • Zhang, (2017), Neurol. Sci., 38, pp. 1629, 10.1007/s10072-017-3020-8
  • Pinto, (2020), Ann. N. Y. Acad. Sci., 1465, pp. 132, 10.1111/nyas.14252
  • Murgia, (2018), Front. Neurol., 9, pp. 348, 10.3389/fneur.2018.00348
  • Machado Sotomayor, M.J., Arufe-Giráldez, V., Ruíz-Rico, G., and Navarro-Patón, R. (2021). Music Therapy and Parkinson’s Disease: A Systematic Review from 2015-2020. Int. J. Environ. Res. Public Health, 18.
  • Molsberry, (2020), Neurology, 95, pp. e2095, 10.1212/WNL.0000000000010523
  • Paknahad, (2020), Complement. Ther. Med., 50, pp. 102366, 10.1016/j.ctim.2020.102366
  • Maraki, (2019), Mov. Disord., 34, pp. 48, 10.1002/mds.27489
  • Yu, (2021), Mov. Disord., 36, pp. 977, 10.1002/mds.28464
  • Agarwal, (2018), J. Nutr. Health Aging, 22, pp. 1211, 10.1007/s12603-018-1094-5
  • Berendsen, (2018), J. Nutr. Health Aging, 22, pp. 222, 10.1007/s12603-017-0909-0
  • Singh, (2020), Neurochem. Res., 45, pp. 1731, 10.1007/s11064-020-03058-3
  • Yin, (2021), Oxidative Med. Cell. Longev., 2021, pp. e9923331, 10.1155/2021/9923331
  • Kujawska, M., and Jodynis-Liebert, J. (2018). Polyphenols in Parkinson’s Disease: A Systematic Review of In Vivo Studies. Nutrients, 10.
  • Youdim, (2003), J. Neurochem., 85, pp. 180, 10.1046/j.1471-4159.2003.01652.x
  • Dihal, (2005), J. Nutr., 135, pp. 1718, 10.1093/jn/135.7.1718
  • Jellinger, (2018), J. Neural Transm., 125, pp. 615, 10.1007/s00702-017-1821-9
  • Hosp, (2021), Brain J. Neurol., 144, pp. 1263, 10.1093/brain/awab009
  • Clavero, (2014), Brain J. Neurol., 137, pp. 2356, 10.1093/brain/awu159
  • Panza, (2019), Nat. Rev. Neurol., 15, pp. 73, 10.1038/s41582-018-0116-6
  • Tsai, (2020), JAMA Neurol., 77, pp. 215, 10.1001/jamaneurol.2019.3812
  • Zhao, (2022), Brain Res., 1788, pp. 147937, 10.1016/j.brainres.2022.147937
  • Obeso, (2021), Nat. Commun., 12, pp. 779, 10.1038/s41467-021-21022-9
  • LeWitt, (2019), Mov. Disord., 34, pp. 1274, 10.1002/mds.27722
  • Sabbagh, (2021), Clin. Cancer Res., 27, pp. 4325, 10.1158/1078-0432.CCR-20-3760
  • Xhima, (2018), Mov. Disord., 33, pp. 1567, 10.1002/mds.101
  • Karakatsani, (2019), J. Control. Release, 303, pp. 289, 10.1016/j.jconrel.2019.03.030
  • Liu, (2021), Nat. Commun., 12, pp. 6394, 10.1038/s41467-021-26754-2
  • Huang, Y., Meng, Y., Pople, C.B., Bethune, A., Jones, R.M., Abrahao, A., Hamani, C., Kalia, S.K., Kalia, L.V., and Lipsman, N. (2022). Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson’s Disease. Pharmaceutics, 14.
  • Folke, J., Ferreira, N., Brudek, T., Borghammer, P., and Van Den Berge, N. (2022). Passive Immunization in Alpha-Synuclein Preclinical Animal Models. Biomolecules, 12.
  • Paolini Paoletti, F., Gaetani, L., and Parnetti, L. (2020). The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers. Biomolecules, 10.
  • Athauda, (2016), Park. Relat. Disord., 32, pp. 1, 10.1016/j.parkreldis.2016.07.019